James Welch

NeXT Software, Inc. develops software. The company is based in Redwood City, CA. The company was founded by Steven Jobs. NeXT Software was acquired by Apple, Inc. on February 07, 1997.

Beluga Composites Corp. develops and manufactures immunodiagnostic testing systems and related therapeutic drug monitoring systems. The firm's products include single water tanks, double water tanks, container series tanks, compartment tanks and accessories. The company is headquartered in Montreal, Canada.

Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA.

Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA.

Avantek, Inc. is an American company that specializes in creating innovative home decor solutions. The private company's flagship product, the Ferrous Wall, allows users to modernize their rooms to a futuristic level by eliminating the need for nails or screws to attach shelves and cabinets. This gives users complete freedom to move around shelves and picture frames. Additionally, Avantek has created the world's first retractable magnetic hinge, which uses magnetic force that can be turned on and off with the click of a button.

Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA.